Some of the most compelling evidence supporting the benefit of GIP/GLP-1R agonism comes from a 40-wk, head-to-head study showing the superiority of tirzepatide over semaglutide for glucose and body weight reduction in patients with T2D (58). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.